摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(4-bromo-2-fluoro-5-methylphenyl)propanoic acid | 881189-66-8

中文名称
——
中文别名
——
英文名称
3-(4-bromo-2-fluoro-5-methylphenyl)propanoic acid
英文别名
——
3-(4-bromo-2-fluoro-5-methylphenyl)propanoic acid化学式
CAS
881189-66-8
化学式
C10H10BrFO2
mdl
——
分子量
261.091
InChiKey
UNHNWIZXVPBTKY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    申请人:SCHWINK Lothar
    公开号:US20140099333A1
    公开(公告)日:2014-04-10
    The present invention relates to pyrrolidinone derivatives. The pyrrolidinone derivatives are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    本发明涉及吡咯烷酮衍生物。这些吡咯烷酮衍生物是GPR119调节剂,适用于预防和/或治疗糖尿病、肥胖、血脂异常及相关疾病。此外,本发明还涉及将吡咯烷酮衍生物用作药物中的活性成分,以及包含它们的药物组合物。
  • Cyclic amine derivative or salt thereof
    申请人:Hayashibe Satoshi
    公开号:US20070197594A1
    公开(公告)日:2007-08-23
    Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely provided are an amine derivative or its salt characterized in that the amine-containing structure A therein bonds to a 2- or 3-cyclic condensed ring (e.g., indane, tetralone, 4,5,6,7-tetrahydrobenzothiophene, 4,5,6,7-tetrahydrobenzofuran, 7,8-dihydro-6H-indeno[4,5-b]furan, 2,3-dihydro- 1 H-cyclopenta[1]naphthalene) via X 1 (bond or lower alkylene); and an NMDA antagonist containing it as an active ingredient thereof.
    提供的化合物是NMDA受体拮抗剂,具有广泛的安全边界,并可用作治疗或预防阿尔茨海默病、脑血管性痴呆、帕森病、缺血性卒中、疼痛等药物。具体提供的是胺衍生物或其盐,其特点在于其中含有胺基结构A,通过X1(键或低碳烷基)与2-或3-环状紧缩环(例如烷、四氢酮、4,5,6,7-四氢苯并噻吩、4,5,6,7-四氢苯并呋喃、7,8-二氢-6H-并[4,5-b]呋喃、2,3-二氢-1H-环戊[1]萘烷)结合;以及含有它作为有效成分的NMDA受体拮抗剂。
  • Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    申请人:Schwink Lothar
    公开号:US08853412B2
    公开(公告)日:2014-10-07
    The present invention relates to pyrrolidinone derivatives. The pyrrolidinone derivatives are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    本发明涉及吡咯烷酮衍生物。这些吡咯烷酮衍生物是GPR119调节剂,可用于预防和/或治疗糖尿病、肥胖症、血脂异常及相关疾病。此外,本发明还涉及将吡咯烷酮衍生物用作药物的活性成分,并包含它们的药物组合物。
  • CYCLIC AMINE DERIVATIVE OR SALT THEREOF
    申请人:Astellas Pharma Inc.
    公开号:EP1795524A1
    公开(公告)日:2007-06-13
    Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely provided are an amine derivative or its salt characterized in that the amine-containing structure A therein bonds to a 2- or 3-cyclic condensed ring (e.g., indane, tetralone, 4,5,6,7-tetrahydrobenzothiophene, 4,5,6,7-tetrahydrobenzofuran, 7,8-dihydro-6H-indeno[4,5-b]furan, 2,3-dihydro-1H-cyclopenta[1]naphthalene) via X1 (bond or lower alkylene); and an NMDA antagonist containing it as an active ingredient thereof.
    本发明提供的化合物是一种具有广泛安全范围的 NMDA 拮抗剂,可作为阿尔茨海默病、脑血管痴呆症、帕森病、缺血性脑中风、疼痛等的治疗剂或预防剂。具体而言,提供了一种胺衍生物或其盐,其特征在于其中的含胺结构 A 与 2-或 3-环缩合环(如茚满、四烯酮、4-环缩合环、5-环缩合环、6-环缩合环、7-环缩合环、8-环缩合环、9-环缩合环)结合、、四酮、4,5,6,7-四氢苯并噻吩、4,5,6,7-四氢苯并呋喃、7,8-二氢-6H-并[4,5-b]呋喃、2,3-二氢-1H-环戊并[1])通过 X1(键或低级亚烷基)结合;以及含有它作为其活性成分的 NMDA 拮抗剂。
  • US8853412B2
    申请人:——
    公开号:US8853412B2
    公开(公告)日:2014-10-07
查看更多